USA flag logo/image

An Official Website of the United States Government

Novel Screen for Targeted CLL Therapeutics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93594
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA141892
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
COGNOSCI, INC.
79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709-2076
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Novel Screen for Targeted CLL Therapeutics
Agency: HHS
Contract: 1R43CA141892-01
Award Amount: $289,114.00
 

Abstract:

DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of all adult leukemia cases. It is characterized by the rele ntless accumulation of monoclonal mature B cells. Tumor cells from B-CLL patients show increased survival rates that have been shown to be due to inhibited apoptosis and alterations of genes involved in cell cycle control and cell survival. When evaluating the signaling pathways that are aberrantly activated in B-CLL cells, it was demonstrated that the kinase Akt is constitutively activated and the overstimulation of Akt results in activation of the NFkB pathway that leads to increased production of NO and inhibited apoptosis. Akt and the NFkB are downregulated by Protein Phosphatase-2a (PP2a). PP2a is a commonly known tumor suppressor that is inhibited by natural inhibitors. Recently, we have shown that the protein SET, a natural inhibitor of PP2a is overex pressed in B-CLL, leading to decreased PP2a activity in B-CLL cells. Reduced PP2a activity would be expected to lead to aberrant signaling through Akt; therefore, pharmacological activation of PP2a by inhibition of SET may provide a novel approach to devel opment of B-CLL therapeutics. Cognosci has developed novel therapeutic peptides with potent anti-inflammatory activity in vitro and in vivo. In mechanistic studies we recently demonstrated that these peptides suppress phosphorylation and the accompanying a ctivation of important inflammatory signaling by acting as antagonists of SET that activate SET. During a preliminary evaluation of several COG compounds in primary CD19+/CD5+ B-CLL cells from patients, we discovered that one of these compounds, (COG112) i s highly and preferentially cytotoxic for human CLL cells with an EC50 of 224 nM and an EC50 for normal B-cells of gt20 uM. Furthermore, this compound reduced white cell counts in an animal model of CLL to validate SET antagonism as a potential therapeutic approach for CLL. We now propose to develop a peptide displacement assay that can be used to screen compound libraries to identify small molecule SET antagonists and screen a diverse 30,000 compound library. PUBLIC HEALTH RELEVANCE: Of the nearly 84,000 c ases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of all adult leukemia cases. It is characterized by the relentless accumulation of monoclonal mature B cells. Tumor cel ls from B-CLL patients show increased survival rates that have been shown to be due to inhibited apoptosis and alterations of genes involved in cell cycle control and cell survival. When evaluating the signaling pathways that are aberrantly activated in B- CLL cells, it was demonstrated that the kinase Akt is constitutively activated and the overstimulation of Akt results in activation of the NFkB pathway that leads to increased production of NO and inhibited apoptosis. Akt and the NFkB are downregulated by Protein Phosphatase-2a (PP2a). PP2a is a commonly known tumor suppressor that is inhibited by natural inhibitors. Recently, we have shown that the protein SET, a natural inhibitor of PP2a is overexpressed in B-CLL, leading to decreased PP2a activity in B-C LL cells. Reduced PP2a activity would be expected to lead to aberrant signaling through Akt; therefore, pharmacological activation of PP2a by inhibition of SET may provide a novel approach to development of B-CLL therapeutics. Cognosci has developed novel therapeutic peptides with potent anti-inflammatory activity in vitro and in vivo. In mechanistic studies we recently demonstrated that these peptides suppress phosphorylation and the accompanying activation of important inflammatory signaling by acting as antagonists of SET that activate SET. During a preliminary evaluation of several COG compounds in primary CD19+/CD5+ B-CLL cells from patients, we discovered that one of these compounds, (COG112) is highly and preferentially cytotoxic for human CLL cells w ith an EC50 of 224 nM and an EC50 for normal B-cells of gt20 uM. Furthermore, this compound reduced white cell counts in an animal model of CLL to validate SET antagonism as a potential therapeutic approach for CLL. We now propose to develop a peptide disp lacement assay that can be used to screen compound libraries to identify small molecule SET antagonists and screen a diverse 30,000 compound library.

Principal Investigator:

Dale J. Christensen
9197650028
DCHRISTENSEN@COGNOSCI.COM

Business Contact:


mikevitek@cognosci.com
Small Business Information at Submission:

COGNOSCI, INC.
COGNOSCI, INC. 79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 562208520
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No